Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OK-101

Recombinant protein · developed by Okyo Pharma

Phase 2 Most advanced trial (none active)
OKYO Developer
2 Registered trials

What is OK-101?

OK-101 is an investigational recombinant protein studied in Dry Eye Disease, Neuropathic Pain.

At a glance

Drug type
Recombinant protein
Therapy area
Neurology, Ophthalmology
Developer
Okyo Pharma Ltd (OKYO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
3GEY66X2W2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06637527 Phase 2 Neuropathic Pain Terminated OKYO
NCT05759208 Phase 2 Dry Eye Disease Completed OKYO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry Eye DiseaseNeuropathic Pain

Follow OKYO, the company behind OK-101

See OKYO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OKYO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.